Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience.

Akshee BatraBrijesh PatelDaniel AddisonLauren A BaldassarreNihar DesaiNeal WeintraubAnita DeswalZeeshan HussainSherry-Ann BrownSarju GanatraVivek AgarwalaPurvish M ParikhMichael FradleyArjun GhoshAvirup Guha

Published in: Open heart (2022)

Antimicrotubular agents are associated with CVAEs, especially in combination chemotherapy regimens. Based on this study, we suggest routine cardiovascular assessment of patients with cancer before initiating antimicrotubular agents in combination therapy.

Keyphrases

combination therapy
clinical practice
locally advanced
squamous cell carcinoma
radiation therapy